Generic Medicine Info
Indications and Dosage
Motion sickness
Adult: Initially, 30 mg 2 hours before travel, then 15 mg 8 hourly during the journey if necessary.
Child: 5-12 years Initially, 15 mg 2 hours before travel, then 7.5 mg 8 hourly during the journey if necessary. >12 years Same as adult dose.

Nausea and vertigo caused by Meniere's disease, Vertigo and vestibular disorders
Adult: 30 mg tid.
Child: 5-12 years 15 mg tid. >12 years Same as adult dose.

Cerebrovascular disorders
Adult: 25 mg tid.

Peripheral circulatory disorders
Adult: 50-75 mg bid to tid. Max: 225 mg daily.
Should be taken with food.
Special Precautions
Patient with hypotension (high dose), Parkinson's disease and porphyria. Children. Pregnancy and lactation.
Adverse Reactions
Significant: Epigastric discomfort.
Gastrointestinal disorders: Nausea, dyspepsia, vomiting, upper abdominal pain, gastrointestinal discomfort.
General disorders and administration site conditions: Fatigue, lethargy.
Hepatobiliary disorders: Cholestatic jaundice.
Investigations: Increased weight.
Musculoskeletal and connective tissue disorders: Muscle rigidity.
Nervous system disorders: Dyskinesia, extrapyramidal disorder, Parkinsonism, tremor, drowsiness, somnolence.
Skin and subcutaneous tissue disorders: Hyperhidrosis, lichenoid keratosis (e.g. lichen planus), subacute cutaneous lupus erythematosus.
Patient Counseling Information
This drug may cause drowsiness, if affected, do not drive or operate machinery.
Symptoms: Consciousness alterations ranging from somnolence to stupor and coma, vomiting, extrapyramidal symptoms, hypotonia; seizures (young children). Management: Symptomatic and supportive treatment. May consider administration of activated charcoal within 1 hour of ingestion.
Drug Interactions
May potentiate sedative effects of CNS depressants and TCAs.
Food Interaction
May enhance sedative effects with alcohol.
Lab Interference
May prevent positive reactions to dermal reactivity indicators if used within 4 days prior to skin testing.
Description: Cinnarizine is a piperazine derivative and a non-competitive antagonist of smooth muscle contractions caused by vasoactive agents like histamine. It has antihistamine, sedative, and Ca-channel blocking activity. It inhibits contraction of smooth muscle by selectively inhibiting Ca influx into depolarised cells, thereby reducing free Ca ions available for the induction and maintenance of contraction.
Absorption: Slowly absorbed. Time to peak plasma concentration: 4 hours.
Distribution: Plasma protein binding: 91%.
Metabolism: Extensively metabolised mainly by CYP2D6.
Excretion: Via faeces (mainly as unchanged drug) and urine (as metabolites). Elimination half-life: 3-6 hours.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Cinnarizine, CID=1547484, (accessed on Jan. 21, 2020)

Store below 30°C.
MIMS Class
Antivertigo Drugs / Peripheral Vasodilators & Cerebral Activators
ATC Classification
N07CA02 - cinnarizine ; Belongs to the class of antivertigo preparations.
Anon. Cinnarizine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 07/11/2019.

Buckingham R (ed). Cinnarizine . Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 07/11/2019.

Joint Formulary Committee. Cinnarizine. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 07/11/2019.

Stugeron Tablet (Johnson & Johnson Sdn Bhd). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. Accessed 07/11/2019.

Stugeron Tablets (Janssen-Cilag NV, Belgium). FDA Ghana. Accessed 07/11/2019.

Disclaimer: This information is independently developed by MIMS based on Cinnarizine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by
  • Celenid
  • Cinnaron
  • Nazin
  • Pharmaniaga Cinnarizine
  • Uphageron
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in